[Adverse effects of subcutaneous administration of erythropoietin solution versus lyophilisate in patients receiving hemodialysis].
Twenty-two patients in haemodialysis were treated with erythropoietin subcutaneously in a double-blinded cross-over study with erythropoietin prepared either as a lyophilisate or an albumin-solution. The aim was to compare local reactions and pain. Both preparations were tolerated well. No major adverse reactions were seen. Erythropoietin albumin-solution was associated with significantly more burning pain than erythropoietin lyophilisate. Allergy does not seem to be involved. Albumin could be the irritative agent.
Jensen
G V
GV
Nefrologisk afdeling, Hvidovre Hospital, København.
Nielsen
B
B
D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D004341:Drug Evaluation; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007279:Injections, Subcutaneous; D011446:Prospective Studies; D006435:Renal Dialysis
D000418:Albumins; D004921:Erythropoietin
Bivirkninger ved subkutan administration af erytropoietinopløsning versus lyofilisat hos haemodialysepatienter.